Letters

Online Drug Sales Quality, Safety,
Privacy
Letters
| Press
| Links
Letters
March
25, 1999
The Honorable
Jane E. Henney, M.D. Commissioner Food and Drug
Administration 5600 Fishers Lane Rockville, Maryland
20857
Dear
Commissioner Henney:
During the past
several years, Internet use has evolved dramatically for the
purchase of a range of products from airline tickets to investments
to almost any item traditionally sold in a store. One group of goods
increasingly sold this way includes pharmaceuticals. Ranging from
both over-the-counter health aids to actual prescription drugs, many
Internet websites now allow consumers using a home computer to
purchase pharmaceuticals once only available through a face-to-face
visit with a doctor and a pharmacist.
The regulation
of pharmacies has traditionally been a state function. States have
generally focused on ensuring that pharmacies observe specific
guidelines to safely dispense medications to the public, and that
they are licensed and operated by qualified and trained staff. State
regulators also ensure that any pharmacy under its jurisdiction
properly stores and safeguards the pharmaceuticals it sells. The
Food and Drug Administration’s (FDA) role in regulating
pharmaceutical sales is focused generally on ensuring that any drugs
sold in the U.S. are FDA approved, properly manufactured, and thus
safe and effective. FDA also ensures that all claims and
instructions by the drug maker for the product are accurate and not
misleading. With the exception of some mail-order operations,
because most pharmacies have operated within a local environment
(e.g., the corner drug store), this federal-state partnership, for
the most part, has been effective in safeguarding public health.
The recent
explosion of online sites that both advertise and sell prescription
drugs across state and even international lines, may be undermining
this regulatory structure. It is not clear who bears the ultimate
responsibility for regulating Internet pharmacies, nor is it clear
what actions are being taken to ensure that the public is being
protected in this new consumer environment. Although some believe
that it is mostly the states that are responsible for shouldering
most of this burden, the cross-border nature of most Internet sites,
coupled with the sheer volume of their activities, may make this an
impossible undertaking. The states alone may not have the necessary
resources, expertise, or jurisdiction to do this job.
Without a doubt,
a host of serious regulatory concerns are posed by Internet
pharmacies. For example, as patients are often required to submit
personal medical data to an online pharmacy before their
prescriptions are processed, highly personal information could be
released (accidentally or deliberately) by an online pharmacy
without the customer’s permission. Some online pharmacies could
contribute to the problem of drug interactions, as the traditional
face-to-face doctor-patient relationship or pharmacist-patient
relationship is replaced by an online computer transaction. Finally,
it remains murky how online pharmacies will process (if at all)
controlled substances, and not be susceptible to abuse by hackers or
other criminal elements. If, as reported, some Internet pharmacies
provide prescription drugs without requiring a patient to actually
visit a doctor or pharmacist, certain controlled substances could be
seriously susceptible to abuse.
Because of our
concerns in this area, we would like you to address the
following:
(1) What agency
or department (at either the state or federal level) does FDA
believe is the primary regulator of Internet pharmacies? For this
question, please also identify and describe the roles of the other
state/federal agencies that may make up this structure.
(2) What
specific activities or functions does FDA believe it is responsible
for with regard to regulating Internet pharmacies? Please describe
both the precise activities now conducted by FDA, and the number of
full-time equivalents (FTEs) dedicated to all identified efforts.
Does FDA believe it has enough resources to conduct the activities
it presently feels are under its jurisdiction in this regard? If,
not, what additional resources does FDA require?
(3) Does FDA
believe that existing laws and regulations, or the present
state/federal regulatory structure, adequately regulate online
pharmacy operations? If not, what are the discrepancies, and what
changes, if any, does FDA believe must be made?
(4) Please
describe FDA’s knowledge regarding the differences between existing
online pharmacies. For example, some reports suggest that most
online pharmacies only fill prescriptions. Other reports, however,
have suggested that some actually provide for a doctor consultation
(for example, a quick questionnaire is submitted over the Internet,
it is reviewed, and then the prescription is then approved and sent
directly to the patient without a doctor ever seeing the patient).
How prevalent is this latter operation? Do any trends appear in
comparing one form of online pharmacy with another?
(5) What is
FDA’s understanding of how these firms deal with issues such as
medical records privacy/protection, the selling of controlled
substances, or drug interactions? How serious are these issues and
what shortcomings, if any, do online pharmacies have with regard to
these issues? Does FDA have any knowledge of how online pharmacies
prevent unqualified persons from receiving prescriptions? Are online
pharmacies more susceptible to fraud or deception? If so, please
explain how?
(6) Finally,
what quality issues does FDA believe relate to the methods used to
ship online pharmaceutical products, and does FDA believe it has
jurisdiction in this area?
Thank you for
your cooperation and attention to our request. If you have any
additional questions about this matter, please have your staff
contact Mr. Christopher Knauer of the Minority staff at (202)
226-3400. We look forward to working with you on this and other
important pharmaceutical integrity and consumer protection
issues.
Sincerely,
JOHN D.
DINGELL RANKING MEMBER COMMITTEE ON COMMERCE
RON
KLINK RANKING MEMBER SUBCOMMITTEE ON OVERSIGHT AND
INVESTIGATIONS
HENRY A.
WAXMAN MEMBER COMMITTEE ON COMMERCE
SHERROD
BROWN RANKING MEMBER SUBCOMMITTEE ON HEALTH AND
ENVIRONMENT
cc:
The Honorable
Tom Bliley, Chairman Committee on Commerce
The Honorable
Michael Bilirakis, Chairman Subcommittee on Health and
Environment
The Honorable
Fred Upton, Chairman Subcommittee on Oversight and
Investigations

|